This site is intended for U.S. Healthcare Professionals only.

EMPLICITI® (elotuzumab) is indicated for the treatment of adult patients with multiple myeloma in combination with:

  • REVLIMID® (lenalidomide) and dexamethasone after one to three prior therapies
  • POMALYST® (pomalidomide) and dexamethasone after at least two prior therapies including lenalidomide and a proteasome inhibitor